ADVERSE EVENT REDUCTION AFTER PERCUTANEOUS INTERVENTION THROUGH USE OF A THROMBINE RECEIVER ANTAGONIST

• 收藏
• 分享

专利权人:

SCHERING CORPORATION

发明人:

ENRICO P. VELTRI,MADHU CHINTALA,JOHN T. STRONY

申请号：

BRPI0809095

公开号：

BRPI0809095A2

申请日:

2008.03.19

申请国别(地区):

BR

年份:

2014

代理人:

摘要：

Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective amount of a thrombin receptor antagonist, such as SCH 530348, to the patient. Administration of a loading dose of about 40 mg of SCH 530348 in as little as one hour prior to the procedure can result in therapeutically effective levels of platelet aggregation.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/